Short answer
Vera Therapeutics, Inc. (VERA) filed an 8-K current report with the SEC on June 2, 2026 reporting Item 8.01 (Other Events). FDA alignment on earlier ORIGIN 3 eGFR analysis for atacicept’s potential full IgA nephropathy approval.
Vera Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA alignment on earlier ORIGIN 3 eGFR analysis for atacicept’s potential full IgA nephropathy approval
- eGFR results expected in Q3 2026, creating the next major clinical catalyst
- Supplemental Biologics License Application planned for Q4 2026, contingent on results
- Regulatory approval remains uncertain, with trial outcomes and FDA review posing material risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vera Therapeutics, Inc. 8-K filings
Get the next VERA 8-K as it lands
Follow VERA for push alerts, or ask the research agent what this filing means.